Trial
NCT00573378
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Chronic Myeloid Leukemia
Intervention
PEG-IFN-a2b
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-25